Opriță R, Diaconescu I B, Lupu G, Lupu A, Cristea B, Bratu M R
"Floreasca" Clinical Emergency Hospital, Bucharest.
Department of Anatomy, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
J Med Life. 2014 Oct-Dec;7(4):477-80.
Screening of known cirrhotics for hepatocellular cancer (HCC) has long been a contentious topic. Studies to date have failed to conclusively prove or disprove the validity of α-fetoprotein (AFP) and hepatic ultrasound as screening mechanisms for HCC among cirrhotics. It is not clear whether these screening mechanisms provide any benefit in terms of reduced morbidity and mortality. Screening for HCC among cirrhotics by using AFP and/or imaging at every 6 months correlate with HCC diagnosis, thus portending better treatment options and an improved prognosis. Screening all the known cirrhotics for HCC may lead to decreased mortality.
对已知肝硬化患者进行肝细胞癌（HCC）筛查长期以来一直是一个有争议的话题。迄今为止的研究未能确凿地证明或反驳甲胎蛋白（AFP）和肝脏超声作为肝硬化患者HCC筛查机制的有效性。目前尚不清楚这些筛查机制在降低发病率和死亡率方面是否有任何益处。每6个月使用AFP和/或影像学对肝硬化患者进行HCC筛查与HCC诊断相关，从而预示着更好的治疗选择和改善的预后。对所有已知的肝硬化患者进行HCC筛查可能会降低死亡率。
